MODULATION OF THE FUNCTION OF HUMAN MDR1 P-GLYCOPROTEIN BY THE ANTIMALARIAL DRUG MEFLOQUINE

Citation
Cd. Riffkin et al., MODULATION OF THE FUNCTION OF HUMAN MDR1 P-GLYCOPROTEIN BY THE ANTIMALARIAL DRUG MEFLOQUINE, Biochemical pharmacology, 52(10), 1996, pp. 1545-1552
Citations number
43
Categorie Soggetti
Pharmacology & Pharmacy",Biology
Journal title
ISSN journal
00062952
Volume
52
Issue
10
Year of publication
1996
Pages
1545 - 1552
Database
ISI
SICI code
0006-2952(1996)52:10<1545:MOTFOH>2.0.ZU;2-5
Abstract
MDR1 P-glycoprotein in membranes of human tumor cells of the CEM/VBL(1 00) line was selectively labelled using photoreactive analogs of verap amil, N-(p-azido-3-[I-125]salicyl)amino-verapamil ([I-125]ASA-V) and p razosin, l)piperazin-1-yl]4-amino-6,7-dimethoxyyquinazoline ([I-125]AS A-P). Mefloquine, a quinolinemethanol antimalarial drug, was shown to inhibit the labelling of P-glycoprotein with an efficiency similar to that for verapamil, a known chemosensitizer. By contrast, chloroquine competed poorly for the binding site on P-glycoprotein. Mefloquine als o inhibited the functional activity of P-glycoprotein. It decreased th e rates of extrusion of [H-3]vinblastine and the fluorescent dyes, flu o-3 acetomethoxy ester and rhodamine 123, from drug-resistant cells an d decreased the level of resistance of these cells to vinblastine. The ability of mefloquine to inhibit P-glycoprotein function may be invol ved in the neurotoxic side-effects occasionally associated with the us e of mefloquine as an antimalarial drug. Copyright (C) 1996 Elsevier S cience Inc.